American Journal of Clinical Dermatology最新文献

{"title":"From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma.","authors":"Turkan Ozturk Topcu, Çiğdem Dinçkal, Zeynep Eroglu","doi":"10.1007/s40257-026-01080-9","DOIUrl":"https://doi.org/10.1007/s40257-026-01080-9","url":null,"abstract":"<p><p>Resistance to BRAF/MEK inhibition remains the central therapeutic challenge in BRAF mutant melanoma. Although combined MAPK-targeted therapy induces rapid and often dramatic tumor responses, most patients ultimately develop progressive disease. Over the past decade, translational studies have fundamentally changed our understanding of this process. Resistance is now recognized not as a single genomic event, but as a biologically heterogeneous and adaptive phenomenon involving tumor cell plasticity, microenvironmental remodeling, and immune evolution. This evolving framework has important clinical implications. Recent randomized sequencing clinical trials have shifted treatment paradigms toward a front-line immune checkpoint blockade for many patients. Similarly, triplet approaches combining MAPK inhibition with immunotherapy have shown heterogenous results on progression-free survival benefit and durable overall survival benefits remain uncertain. At the same time, therapeutic options after progression are rapidly expanding and include ERK inhibitors, next-generation pan-RAF inhibitors, vertical pathway targeting strategies, and emerging approaches directed against persister-cell biology and adaptive resistance states. In this review, we integrate current insights from genomic, transcriptomic, single-cell, and spatial studies with the most relevant clinical trial data to provide a contemporary framework for understanding resistance to MAPK-targeted therapy in melanoma. We further discuss how adaptive monitoring approaches, including circulating tumor DNA analysis, may help guide future biomarker-driven and evolution-informed treatment strategies.Author names: Please confirm if the author names are presented accurately and in the correct sequence (given name, middle name/initial, family name). Author 1 Given name: [Turkan Ozturk] Last name [Topcu]. Also, kindly confirm the details in the metadata are correct. Please correct Author 1's name designation as follows: Given name: Turkan; Family name: Ozturk Topcu. Please update both the article and the metadata accordingly.Kindly check and confirm whether the organization division, organization name, street and postcode in affilition 3 has been processed correctly and amend if necessary.Corrected.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149214852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Predictors of Sustained Response After Dose Tapering of Targeted Therapies in Moderate-to-Severe Atopic Dermatitis: A Systematic Review.","authors":"Marina Mordehachvili Burlá, Lyria de Oliveira Rosa, Beatriz Ximenes Mendes, Fernanda Valeriano Zamora, Joe K Tung, Maria Tsoukas, Roger Haber","doi":"10.1007/s40257-026-01085-4","DOIUrl":"https://doi.org/10.1007/s40257-026-01085-4","url":null,"abstract":"<p><strong>Background: </strong>Moderate-to-severe atopic dermatitis (AD) often requires prolonged systemic therapy. As disease control is achieved, optimizing dose tapering and identifying factors associated with sustained response are increasingly relevant.</p><p><strong>Objective: </strong>The aim was to identify factors associated with maintained disease control following dose tapering of biologics and small-molecule inhibitors used for AD.</p><p><strong>Methods: </strong>A systematic review was conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE, Embase, and the Cochrane Library were searched from 2010 to present, along with manual reference screening. Studies evaluating dose tapering or withdrawal of dupilumab, tralokinumab, lebrikizumab, abrocitinib, baricitinib, or upadacitinib were included. Extracted data included study design, patient characteristics, tapering or withdrawal strategies, and follow-up duration. Outcomes of interest were sustained response, relapse rates, and predictors of long-term disease control.</p><p><strong>Results: </strong>Nineteen studies (4375 patients) were included. Sustained response rates post-tapering varied across abrocitinib (0-60%), baricitinib (45-61%), dupilumab (30-100%), lebrikizumab (67-82%), tralokinumab (25-50%), and upadacitinib (47-61%). Lower baseline disease activity and early clinical improvement were frequently identified as potential predictors of durability. For dupilumab, older age, lower body mass index (BMI), and prurigo nodularis phenotype were associated with sustained response in selected cohorts. For tralokinumab, longitudinal stability across multiple visits outperformed single-time-point assessments. Abrocitinib outcomes favored milder disease without allergic comorbidities, whereas upadacitinib showed higher relapse rates after withdrawal.</p><p><strong>Conclusions: </strong>In selected patients with moderate-to-severe AD achieving stable disease control, dose tapering appeared to preserve efficacy more frequently than abrupt withdrawal, although response rates and durability varied across therapeutic classes, study designs, and outcome definitions. Predictors of sustained response were drug specific, and longer prospective studies are needed to inform individualized tapering strategies.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ritlecitinib: A Review in Severe Alopecia Areata.","authors":"Hannah A Blair","doi":"10.1007/s40257-026-01075-6","DOIUrl":"https://doi.org/10.1007/s40257-026-01075-6","url":null,"abstract":"<p><p>Ritlecitinib (Litfulo^®) is an oral dual inhibitor of Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases. It is approved in several countries worldwide for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In the pivotal, randomized, double-blind, placebo-controlled, phase 2b/3 ALLEGRO trial in adults and adolescents with alopecia areata with ≥ 50% scalp hair loss, ritlecitinib 50 mg once daily significantly increased the proportion of patients achieving ≤ 20% scalp hair loss at week 24 compared with placebo. Ritlecitinib also improved patient-reported outcomes, including Patient's Global Impression of Change responses. Response rates for key efficacy outcomes in the pivotal trial continued to increase through 48 weeks and were sustained for up to 3 years in the open-label phase 3 ALLEGRO-LT trial. Longer-term treatment was also associated with improvements in health-related quality of life. Ritlecitinib was generally well tolerated, with most adverse events being of mild or moderate severity. While further data are needed to fully characterize long-term safety, currently available data suggest that ritlecitinib is a valuable new option for the treatment of severe alopecia areata, including in adolescents for whom approved treatment options are limited.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.","authors":"Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A Mesinkovska, Carle Paul, Yankun Gong, Susan D Anway, Helen Tran, Robert Wolk, Samuel H Zwillich, Alexandre Lejeune","doi":"10.1007/s40257-026-01070-x","DOIUrl":"https://doi.org/10.1007/s40257-026-01070-x","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149057230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser Therapy for Cutaneous Vascular Anomalies: Efficacy, Safety, and Innovations.","authors":"Mustufa Jafry, C William Hanke","doi":"10.1007/s40257-026-01069-4","DOIUrl":"https://doi.org/10.1007/s40257-026-01069-4","url":null,"abstract":"<p><p>Cutaneous vascular anomalies comprise a heterogeneous spectrum of congenital or early-onset vascular lesions, including capillary, venous, lymphatic, and arteriovenous malformations, as well as selected vascular tumors such as infantile hemangiomas. Aberrant vascular development frequently produces conspicuous lesions with attendant psychosocial, cosmetic, and sometimes functional burden. Over the past several decades, laser- and light-based interventions have become fundamental to management, with progressive refinements yielding notable gains in both efficacy and safety. This narrative review evaluates the clinical performance, safety profile, and recent technological advances of laser therapies for cutaneous vascular anomalies, with particular attention to pulsed dye laser (PDL), neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers, intense pulsed light (IPL), and selected emerging platforms including potassium titanyl phosphate (KTP) lasers and multimodal strategies. Relevant literature was reviewed with emphasis on efficacy by lesion subtype, patient selection, peri-procedural planning, post-treatment care, and complication mitigation. PDL remains the reference modality for many superficial vascular lesions, including port-wine stains and superficial infantile hemangiomas, whereas Nd:YAG lasers offer superior penetration for deeper or bulkier lesions at the cost of greater discomfort and a narrower safety margin. IPL and KTP devices provide additional versatility, particularly for superficial telangiectatic and erythematous lesions. Emerging strategies-including dual-wavelength regimens, next-generation large-spot devices, and adjunctive approaches for treatment-resistant lesions-continue to expand the therapeutic armamentarium. When tailored to lesion morphology, skin phototype, patient age, and anatomic site, laser therapy remains a safe and effective cornerstone in the management of cutaneous vascular anomalies. Ongoing innovation and more personalized treatment algorithms are expected to further improve durability of clearance, reduce recurrence, and refine long-term outcomes.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosacea in Patients with Skin of Color: Diagnosis and Management.","authors":"Devina Lohani, Justin W Marson, Hilary E Baldwin","doi":"10.1007/s40257-026-01066-7","DOIUrl":"https://doi.org/10.1007/s40257-026-01066-7","url":null,"abstract":"<p><p>Rosacea is a chronic central face dermatosis caused by a combination of dysregulated innate and adaptive immunity and hyperreactive cutaneous neurovasculature. Although classically associated with lighter skin phototypes, rosacea may affect up to 2-4% of Black, Asian, Pacific Islander, and Hispanic/Latino American populations and its prevalence is likely underestimated given our current diagnostic reliance on phenotypic expression (e.g., fixed erythema with or without intermittent exacerbations, flushing, and/or telangiectasias) that may be difficult to appreciate in more heavily pigmented skin. In patients with richly pigmented skin, a careful history of symptoms to assess the minor/secondary criteria (i.e., burning or stinging, edema, dryness, flushing, low tolerance for over-the-counter products, symptoms with classic 'triggers', family history and/or ocular symptoms), along with patient participation during the physical exam to establish their baseline skin tone, may facilitate diagnosis. Rosacea treatment regimens are centered around presentation and can include over-the-counter agents, lifestyle modifications, prescription topical, systemic, and procedural therapies. Optimal regimens may be tailored to best address patient-perceived disease severity and concerns and to minimize any further irritation/inflammation which may drive pigmentary alteration.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis","authors":"Manh Duc Hoang,&nbsp;Thi Oanh Bui,&nbsp;Van Tu Dao,&nbsp;Van Quang Le,&nbsp;Céleste Lebbé,&nbsp;Guilhem Bousquet","doi":"10.1007/s40257-026-01068-5","DOIUrl":"10.1007/s40257-026-01068-5","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 5","pages":"1131 - 1131"},"PeriodicalIF":11.4,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01068-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Hormones in Psoriatic Disease: A Systematic Review.","authors":"Yueqiao Cai, Hui Xiao, Yinli Zhou, Ziyi Xiao, Kun Hu, Zhiru Zhou, Leyi Huang, Yixuan Tong, Muyao Tang, Ting Long, Yi Xiao","doi":"10.1007/s40257-026-01067-6","DOIUrl":"https://doi.org/10.1007/s40257-026-01067-6","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis (PsO) and psoriatic arthritis (PsA) are closely related inflammatory diseases with marked sex differences. Disease activity often fluctuates during major endocrine transitions such as pregnancy and menopause. However, the impact of sex hormones on PsO and PsA remains incompletely understood.</p><p><strong>Objective: </strong>To summarize clinical associations and immunomodulatory roles of sex hormones in PsO and PsA.</p><p><strong>Methods: </strong>Following PRISMA guidelines, we systematically searched PubMed, Embase, Web of Science, Scopus, and the Cochrane Library from inception to 10 December 2025. Eligible studies included clinical and supportive preclinical evidence on estrogens, progesterone, androgens, prolactin, and related hormonal factors in PsO and PsA. Clinical study quality was assessed using Joanna Briggs Institute tools.</p><p><strong>Results: </strong>A total of 72 studies were included. High-estrogen states (e.g., pregnancy) are associated with improvement or low disease activity in PsO, whereas postpartum and menopause are high-risk periods for relapse. Evidence for PsA is limited and inconsistent, although postpartum may be a higher-risk window for worsening. Evidence on menopausal hormone therapy remained inconclusive and appeared to vary by formulation, timing, and population; experimental lesion-targeted hormonal approaches are being explored. In male patients, circulating testosterone levels are frequently reduced and may be associated with disease severity, metabolic comorbidities, and reproductive dysfunction. Prolactin may also contribute to psoriatic inflammation, particularly through stress-related and local tissue pathways.</p><p><strong>Conclusions: </strong>Fluctuations in estrogen and progesterone associated with female life stages, as well as reduced androgen levels in males, may influence disease activity. PsO often improves during pregnancy but may worsen postpartum or around menopause, while altered prolactin signaling may also be involved. Evidence for PsA and hormone-based interventions remains limited and inconsistent. Clinicians should consider closer monitoring during major hormonal transitions, while further mechanistic and clinical validation is needed to clarify the role of sex hormones in psoriatic disease.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Aging in Skin of Color: A Narrative Review.","authors":"Nisal Vipulaguna, Ferdos Abdulkader, Eryn Patin, Saroja Rao, Nada Elbuluk, Arianne Shadi Kourosh, Tasneem F Mohammad, Michelle Rodrigues","doi":"10.1007/s40257-026-01064-9","DOIUrl":"https://doi.org/10.1007/s40257-026-01064-9","url":null,"abstract":"<p><p>Cutaneous aging is a complex biological process that follows a distinct trajectory in skin of color (Fitzpatrick skin types III-VI) compared with lighter skin types. While increased epidermal melanin provides partial photoprotection and often delays the development of rhytides, skin of color is disproportionately affected by pigmentary sequelae of aging, including mottled hyperpigmentation, solar lentigines, melasma, and post-inflammatory hyperpigmentation. These differences are further complicated by gaps in skin of color-specific clinical training, as well as heterogeneity across ethnic subtypes, cultural practices, and social determinants, making management of aging in skin of color uniquely challenging. In this narrative review, we summarize contemporary evidence on the clinical and histologic features of skin of color, key mechanisms underlying intrinsic aging and photoaging, and practical strategies to address common aging concerns in this population. We highlight that long-wavelength UVA (UVA1) and visible light can induce oxidative stress and persistent pigmentation, and that conventional sunscreens may inadequately protect against these wavelengths. Accordingly, broad-spectrum photoprotection, particularly formulations that provide visible-light coverage (e.g., tinted sunscreens with iron oxides), should be emphasized as a cornerstone intervention. We also review topical agents (including retinoids and pigment modulators), oral antioxidants, and procedural therapies, underscoring the need for cautious selection and technique given the higher propensity for post-inflammatory hyperpigmentation and scarring. These strategies are underpinned by the need for individualized counseling, culturally responsive education, and improved skin of color-specific training for dermatologists globally.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial.","authors":"Ling Han, Haihong Qin, Xiaonian Lu, Litao Zhang, Linfeng Li, Hongfang Han, Jinyan Wang, Xinsuo Duan, Dongjie Sun, Wenlin Yang, Hong Ren, Xiaohua Wang, Chao Ci, Yu Wang, Xiuping Han, Wenhao Yin, Chunshui Yu, Min Zhang, Jianjian Zhu, Liming Wu, Zudong Meng, Tongxiang Zeng, Huiping Wang, Yunyun Shan, Yangfeng Ding, Wenli Feng, Xiaoli Zhang, Guoqiang Zhang, Qing Guo, Hao Cheng, Chao Ji, Ruihua Fang, Xiuqin Dong, Xiaofang Zhu, Tiechi Lei, Xueyuan Yang, Rong Xiao, Zhijun Liu, Xiaohua Tao, Rixin Chen, Jing Lou, Yanli Liu, Jing Zhang, Jinhua Xu","doi":"10.1007/s40257-026-01057-8","DOIUrl":"https://doi.org/10.1007/s40257-026-01057-8","url":null,"abstract":"<p><strong>Background: </strong>SSGJ-608 is a recombinant, humanized, immunoglobulin G1 monoclonal antibody that targets human interleukin-17A with high specificity and high affinity.</p><p><strong>Objective: </strong>We aimed to evaluate the efficacy and safety of SSGJ-608 in patients with moderate-to-severe psoriasis in China.</p><p><strong>Methods: </strong>Adult patients aged 18 years or older with moderate-to-severe plaque psoriasis were randomly assigned (2:2:1) to receive subcutaneous injections of placebo (placebo group), 80 mg of SSGJ-608 every 2 weeks after a starting dose of 160 mg at week 0 (608A group), or 160 mg of SSGJ-608 every 4 weeks (608B group). At week 12, patients in the 608A group received SSGJ-608 80 mg every 4 weeks, patients in the 608B group received SSGJ-608 160 mg every 8 weeks, and patients in the placebo group were re-allocated (1:1) to either the 608A or 608B group to receive 608 80 mg every 4 weeks (with an additional 160-mg loading dose of SSGJ-608 at week 12) or 160 mg every 8 weeks. All patients received treatment until week 48. The primary endpoints were a ≥75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI75) and a static Physicians Global Assessment score of 0/1 (sPGA 0/1) at week 12.</p><p><strong>Results: </strong>A total of 458 patients were randomly assigned to either the 608A group (n = 184), the 608B group (n = 183), or the placebo group (n = 91). At week 12, compared with those in the placebo group, a greater proportion of patients in the 608A group and in the 608B group achieved the primary endpoints of PASI75 (95.1% vs 93.4% vs 8.8%) and sPGA of 0 or 1 (76.1% vs 67.2% vs 1.1%). At week 52, PASI75 was maintained by 93.7% in the 608A group and 93.6% in the 608B group, sPGA of 0 or 1 was maintained by 89.3% in the 608A group and 89.4% in the 608B group, PASI90 was maintained by 92.6% in the 608A group and 92.5% in the 608B group, respectively. Both treatment groups demonstrated a favorable safety profile, with no increase in risk observed with longer drug exposure.</p><p><strong>Conclusions: </strong>SSGJ-608 showed rapid and robust clinical response at week 12 and through week 52, and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov Identifiers: NCT05536726.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":11.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148787191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}